Gedeon Richter PLC

AbbVie presented new real-world data at Psych Congress 2026 in New Orleans supporting the effectiveness of VRAYLAR (cariprazine) in major depressive disorder and bipolar I depression. In the prospective observational CReW BP-I study of 118 adults with bipolar I depression, mean Montgomery-Åsberg Depression Rating Scale scores fell from a baseline of 32.2 to 19.9 at week 12, a change of -12.92 with p<0.0001, while Functional Assessment Short Test scores dropped from 43.4 to 30.7, a change of -13.11 with p<0.0001; nausea and dizziness were the most common treatment-emergent adverse events at 5.1% each. In an interim analysis of 76 participants in the ongoing ProACt study of adjunctive VRAYLAR in MDD, mean PHQ-9 scores decreased from 15.7 at baseline to 7.1 at week 6, a model-estimated change of -9.29 with a 95% CI of -11.13 to -7.45 and p<0.001, and 76.3% of patients reached minimal or mild depression severity by week 6. AbbVie also presented an anchored matching-adjusted indirect comparison of cariprazine and lumateperone in MDD, final long-term pediatric safety data, and patient preference research on treatment after inadequate antidepressant response. VRAYLAR, developed jointly by AbbVie and Gedeon Richter Plc, has been used by more than 150,000 clinicians to treat more than 1.9 million patients since its 2015 approval.